ACTI — Active Biotech AB publ Share News
0.000.00%
Last trade - 00:00- SEK367.52m
- SEK314.32m
Brief: Active Biotech Reports Intriguing Intraocular Levels in Laquinimod Eye Drops Study
Brief: Active Biotech Q2 EBIT Loss at SEK 10.7 Million
Brief: Active Biotech Enters Agreement For Clinical Study Of Tasquinimod In Myelofibrosis
Brief: Active Biotech Says Naptumomab, Docetaxel Results To Be Presented At ASCO 2024
Brief: Active Biotech Acquires Rights To Patents Of Tasquinimod In Combination Therapy
Brief: Active Biotech Q4 Operating Loss Narrows To SEK 12.8 Mln
Brief: Active Biotech Announces Outcome Of Rights Issue
Brief: Active Biotech Announces Rights Issue Of SEK 51 Mln
Brief: Active Biotech Q3 Operating Loss Narrows To SEK 10.6 Mln
Brief: Active Biotech Says Laquinimod Shown To Be Safe And Tolerable
Brief: Active Biotech Q2 Oper Loss Narrows To SEK 11.3 Mln
Brief: Active Biotech Enters Into Clinical Trial Collaboration Agreement
Brief: Active Biotech: Safety And Ocular Biodistribution Support Development Of Laquinimod Eye Drops For Inflammatory Eye Disorders
Brief: Active Biotech Q1 Loss per Share at SEK 0.04
Brief: Active Biotech: Safety And Preliminary Activity Of Naptumomab In Combination With Durvalumab Presented At AACR 2023
Brief: Active Biotech Q4 Operating Loss Narrows To SEK 15.2 Million
Brief: Active Biotech Confirms Positive Clinical Safety Profile Of Laquinimod Eye Drops
Brief: Active Biotech Q3 Operating Loss At SEK 13.4 Million
Brief: Active Biotech Receives U.S. Patent For Laquinimod In Eye Disorders